## What are clinical research studies?

Clinical research studies help determine if an investigational medicine is safe and effective. Before a doctor prescribes a new medicine, it must go through several phases of clinical research. The rules and ethics that doctors must follow to practice medicine also apply to clinical research studies.

**Participation in clinical research studies is a choice. Volunteers may stop participating at any time.**

# CONQUEST

**Scleroderma Research Foundation Platform Clinical Trial**

**Thank you for considering this quest.**

**For more information, contact:**

## Join the quest to advance systemic sclerosis research

Consider enrolling in the CONQUEST study for interstitial lung disease associated with systemic sclerosis.

V2 | 29APR2024 | SRF201

## What is the CONQUEST study?

Over time, the CONQUEST study will research several investigational medicines in volunteers with systemic sclerosis.

- Only research studies can use investigational medicines because health and regulatory authorities have not approved them for public use

Currently, the CONQUEST study is evaluating 2 investigational medicines for interstitial lung disease associated with systemic sclerosis (SSc-ILD) using 1 study plan, called the master study protocol.

Each investigational medicine has its own "subprotocol" with details that only apply to the study group.

- Subprotocols are extensions of the master study protocol

By sharing study resources, these investigational medicines may become available to patients faster.

## Will I receive an investigational medicine?

The CONQUEST study is researching 2 investigational medicines, each a potential SSc-ILD therapy.

If you are eligible and decide to join, you will be assigned at random to 1 of the available investigational medicines or a placebo. Placebos look like the investigational medicine, but they do not have therapeutic effects. Study staff will give you more information about the investigational medicines and dosing instructions.

## Who can join the study?

Candidates with the following criteria may be able to join the study:

- Adults ages 18 or older
- SSc-ILD diagnosis
- SSc symptoms that began within the past 5 years
  - This study permits earlier onset of Raynaud's disease

Other criteria apply.

## What can study participants expect?

CONQUEST study participation is about 1 year. You will travel to a study center periodically to take study tests.

The following timeline is an estimate. Lengths may vary for some study groups.

- Screening: 1 month (4 weeks)
- Receive investigational medicine or placebo: about 12 months (52 weeks)
- Attend all follow-up visits: frequency of visits depends on the investigational medicine